TRCT
MRKR icon

Tower Research Capital (TRC)’s Marker Therapeutics MRKR Stock Holding History

Tower Research Capital (TRC)’s Portfolio MRKR Stock Details MRKR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.19K Sell
810
-2,327
-74% -$3.39K ﹤0.01% 4869
2026
Q1 		$4.08K Buy
3,137
+2,423
+339% +$3.84K ﹤0.01% 4230
2025
Q4 		$1.06K Buy
+714
New +$809 ﹤0.01% 4765
2025
Q3 		– Sell
-3,375
Closed -$5.16K – 5469
2025
Q2 		$5.16K Buy
3,375
+185
+6% +$237 ﹤0.01% 4221
2025
Q1 		$3.92K Buy
3,190
+1,930
+153% +$3.54K ﹤0.01% 4327
2024
Q4 		$3.92K Sell
1,260
-248
-16% -$878 ﹤0.01% 4562
2024
Q3 		$4.25K Sell
1,508
-359
-19% -$1.42K ﹤0.01% 4624
2024
Q2 		$10.1K Buy
1,867
+534
+40% +$2.27K ﹤0.01% 4175
2024
Q1 		$5.73K Buy
1,333
+21
+2% +$92 ﹤0.01% 4499
2023
Q4 		$7.22K Buy
1,312
+685
+109% +$2.32K ﹤0.01% 4645
2023
Q3 		$2.85K Sell
627
-2,165
-78% -$12.1K ﹤0.01% 5093
2023
Q2 		$8.65K Sell
2,792
-1,456
-34% -$2.53K ﹤0.01% 4394
2023
Q1 		$3K Buy
4,248
+3,603
+559% +$8.57K ﹤0.01% 5208
2022
Q4 		$2K Buy
+645
New +$2.23K ﹤0.01% 5391
2022
Q3 		– Sell
-2,231
Closed -$8.19K – 6328
2022
Q2 		$7K Buy
+2,231
New +$7.42K ﹤0.01% 4809
2022
Q1 		– Hold
0
– – – 6386
2021
Q4 		– Sell
-772
Closed -$13K – 6397
2021
Q3 		$13K Sell
772
-214
-22% -$4.38K ﹤0.01% 4090
2021
Q2 		$28K Sell
986
-2,279
-70% -$60K ﹤0.01% 3569
2021
Q1 		$73K Buy
3,265
+2,050
+169% +$46.9K ﹤0.01% 2824
2020
Q4 		$18K Sell
1,215
-2,112
-63% -$32.8K ﹤0.01% 3933
2020
Q3 		$50K Buy
3,327
+2,723
+451% +$49.7K ﹤0.01% 3543
2020
Q2 		$12K Buy
604
+146
+32% +$3.19K ﹤0.01% 3934
2020
Q1 		$9K Sell
458
-1,116
-71% -$28.4K ﹤0.01% 2078
2019
Q4 		$45K Buy
1,574
+1,563
+14,209% +$56.9K ﹤0.01% 1411
2019
Q3 		$1K Buy
+11
New +$650 ﹤0.01% 3894
2019
Q1 		– Sell
-3
Closed – – 4100
2018
Q4 		$0 Sell
3
-47
-94% -$3.43K ﹤0.01% 4160
2018
Q3 		$5K Buy
+50
New +$4.29K ﹤0.01% 3126

Other funds holding MRKR

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
CIA
Concurrent Investment Advisors Tampa, Florida $11.8B AUM 31.86% 1-Year Est. Return

Tower Research Capital (TRC)'s MRKR Position: Q2 2026 in Review

Tower Research Capital (TRC) reduced its Marker Therapeutics (MRKR) stake by 74% in Q2 2026, selling an estimated $3.39K and leaving 810 shares worth $1.19K. The position accounts for ﹤0.01% of the portfolio, ranked #4869.

Tower Research Capital (TRC) first reported a position in MRKR in Q3 2018 and has held it in 26 quarters since. The position peaked at $73K in Q1 2021. 35 funds tracked by Wall St. Rank hold MRKR as of Q2 2026.

  • Tower Research Capital (TRC) held 810 shares of Marker Therapeutics worth $1.19K as of Q2 2026.
  • Tower Research Capital (TRC) sold 2,327 Marker Therapeutics shares in Q2 2026, an estimated $3.39K.
  • Marker Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #4869 holding.
  • Tower Research Capital (TRC) first reported a position in Marker Therapeutics in Q3 2018 and has held it in 26 quarters since.
  • Tower Research Capital (TRC)'s Marker Therapeutics position peaked at $73K in Q1 2021.
  • 35 funds tracked by Wall St. Rank held Marker Therapeutics as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.